ModifiedCignaPolicy IP0621

Glucagon-Like Peptide-1 Agonists BMI ≥ 32

Coverage criteria and authorization requirements for Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide) when used for weight loss or FDA-approved indications, including adult and pediatric obesity, cardiovascular risk reduction, and select comorbid conditions; applies to Cigna-administered plans as described.

Policy Summary

PayerCigna

PolicyGlucagon-Like Peptide-1 Agonists BMI ≥ 32

Policy CodePolicy IP0621

Change TypeMaterial revisions to comorbidity definitions, concomitant therapy exclusions, and continuation durations

Effective DateSep 15, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documentation of baseline BMI, trial of behavioral modification (≥3 months), and required comorbidity or weight-loss response criteria.

SourceLink

POLICY UPDATE CHANGES

Wegovy coverage for reduction of major adverse cardiovascular events in patients with established cardiovascular disease who are overweight or obese was added and then later removed from the policy.

Metabolic-associated steatotic liver disease (new nomenclature for NAFLD) was added to the list of weight-related comorbidities and comorbidity timing was clarified to 'baseline or current'.

Concomitant use with other FDA‑approved weight-loss medications and concomitant use of multiple GLP-1 or GLP-1/GIP agonists was clarified as not recommended/not covered.

Continuation approval durations for Wegovy and certain pediatric/continuation dosing criteria were changed to 1 year and some dosing criteria were removed.

3Drugs named

BMI ≥ 32Primary adult BMI threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

BMI ≥27 + ≥2Alternate adult pathway

RequiredBehavioral program required

8 monthsInitial approval (weight loss)

1 yearContinuation approval

Coverage Criteria

Saxenda: Initial and Continuing Therapy

Saxenda is covered when ONE of the following is met (I, II, or III). Saxenda FDA‑approved weight‑loss criteria (adult):

Saxenda Initial Therapy (Adult): Approve for 4 months if ALL are met

i. Patient is ≥ 18 years of age; ii. Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; iii. At baseline patient had a BMI ≥ 32 kg/m2 OR at baseline patient had a BMI ≥ 27 kg/m2 and at baseline had (or currently has) at least two specified weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, COPD, metabolic dysfunction-associated steatotic liver disease/NAFLD, polycystic ovarian syndrome, or coronary artery disease); iv. Medication will be used concomitantly with behavioral modification and a reduced‑calorie diet. Documentation required.

Saxenda Continuing Therapy (Adult): Approve for 1 year if ALL are met

i. Patient is ≥ 18 years of age; ii. At baseline patient had a BMI ≥ 32 kg/m2 OR at baseline patient had a BMI ≥ 27 kg/m2 and at baseline had (or currently has) ≥2 specified weight‑related comorbidities; iii. Patient has lost ≥4% of baseline body weight; iv. Medication will be used concomitantly with behavioral modification and a reduced‑calorie diet. Documentation required.

Saxenda Initial Therapy (Pediatric 12 to <18): Approve for 4 months if ALL are met

i. Patient is ≥ 12 years and < 18 years; ii. Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; iii. At baseline patient had a BMI ≥ 95th percentile for age and sex; iv. Medication will be used concomitantly with behavioral modification and a reduced‑calorie diet. Documentation required.

Saxenda Continuing Therapy (Pediatric 12 to <18): Approve for 1 year if ALL are met

i. Patient is ≥ 12 years and < 18 years; ii. At baseline patient had a BMI ≥ 95th percentile for age and sex; iii. Patient has had a reduction in BMI of ≥1% from baseline; iv. Medication will be used concomitantly with behavioral modification and a reduced‑calorie diet. Documentation required.

Wegovy: Initial and Continuing Therapy; CV risk reduction

Wegovy covered for weight loss and for reduction in major adverse CV events per FDA indications.

Wegovy Initial Therapy (Adult - weight loss): Approve for initial period (7–8 months depending on section) if ALL are met

Wegovy Continuing Therapy (Adult - weight loss): Approve for 1 year if ALL are met

i. Patient is ≥ 18 years of age; ii. At baseline patient had a BMI ≥ 32 kg/m2 OR at baseline patient had a BMI ≥ 27 kg/m2 and at baseline had (or currently has) ≥2 specified weight‑related comorbidities; iii. Patient has lost ≥5% of baseline body weight; iv. Medication will be used concomitantly with behavioral modification and a reduced‑calorie diet. Documentation required.

Wegovy Initial Therapy (Pediatric 12 to <18): Approve for initial period (7 months) if ALL are met

Weight Loss in an Adult with Obesity or Overweight — Initial Therapy

Approve for 8 months if the patient meets ALL of the following:

Initial Therapy criteria

Age: Patient is ≥ 18 years of age≥18 yrs
documentation required
Behavioral modification: Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
documentation required
BMI/comorbidity: Patient meets either (a) at baseline BMI ≥ 32 kg/m2 OR (b) at baseline BMI ≥ 27 kg/m2 AND at baseline has ≥2 specified weight‑related comorbidities (hypertension, type 2 diabetes, dyslipidemia, OSA, cardiovascular disease, knee osteoarthritis, asthma, COPD, metabolic dysfunction‑associated steatotic liver disease/NAFLD, PCOS, or coronary artery disease)

Weight Loss in an Adult — Continuing Therapy with Zepbound (example continuation rules)

Approve for 1 year if the patient meets ALL of the following:

Continuation Therapy criteria

Age: Patient is ≥ 18 years of age≥18 yrs
documentation required
Baseline BMI/comorbidity: At baseline patient had BMI ≥ 32 kg/m2 OR at baseline BMI ≥ 27 kg/m2 with ≥2 weight‑related comorbidities
documentation required
Weight loss response: Patient has lost ≥5% of baseline body weight≥5%
documentation required; product‑specific thresholds may vary (e.g., Saxenda ≥4%)

Obstructive Sleep Apnea (Moderate to Severe) in a Patient with Obesity

Approve for 1 year if Initial Therapy criteria are met:

OSA Initial Therapy

Age: Patient is ≥ 18 years of age≥18 yrs
documentation required
Current BMI: Patient has a current BMI ≥30 kg/m2≥30 kg/m2
documentation required
Sleep study demonstrating diagnosis of moderate to severe OSA and apneahypopnea index ≥15 events/hour
documentation required

Coadministration of GLP‑1 and GLP‑1/GIP agonists is not recommended; these products should not be used together. The policy specifies that none of the GLP‑1 or GLP‑1/GIP agonists are recommended for coadministration with other GLP‑1 or GLP‑1/GIP agonists, and prescribers should avoid combining these agents when seeking coverage under this policy.

Saxenda, Wegovy, and Zepbound are not medically necessary for any use not specified in this policy. The policy explicitly lists that these agents are not covered for other uses and that concomitant use with other FDA‑approved weight‑loss medications is not recommended.

Concomitant use of Saxenda, Wegovy, or Zepbound with other medications FDA‑approved for weight loss is considered not recommended/not medically necessary. Likewise, combining multiple GLP‑1 or GLP‑1/GIP agonists (coadministration of these classes) is not recommended and is treated as not covered under this policy.

Coding and Thresholds

inv-09: Adult BMI thresholds

Primary adult BMI thresholdBaseline BMI ≥ 32 kg/m2 (documentation required)

Alternate adult pathwayBaseline BMI ≥ 27 kg/m2 PLUS at baseline had (or currently has) ≥2 specified weight-related comorbidities (documentation required)

Age requirementPatient is ≥ 18 years of age (documentation required)

Behavioral program prerequisiteTrial of behavioral modification and dietary restriction for at least 3 months (documentation required)

inv-10: Pediatric BMI threshold

Pediatric BMI threshold (age 12–<18)Baseline BMI ≥ 95th percentile for age and sex (documentation required)

Provider Actions & Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Saxenda, Wegovy, and Zepbound per the policy authorization criteria. Submit supporting documentation with the prior authorization request.

Prior authorization required per policy IP0621

Documentation Required

Documentation must be provided to support BMI and baseline measures, comorbidities, behavioral modification engagement, weight loss response during initial therapy, and any condition-specific testing (e.g., sleep study results for obstructive sleep apnea, cardiovascular event history for secondary prevention). Acceptable documentation includes chart notes, prescription claim records, prescription receipts, and other clinical records.

Baseline BMI and documentation of baseline prior to any GLP-1/GLP1–GIP agonist
Evidence of at least 3 months behavioral modification and dietary restriction

Initial Therapy Criteria

Initial therapy requirements

Initial approval durations and criteria differ by product and indication; behavioral program engagement is required.

Initial therapy requirements: See product‑specific initial therapy nodes

Behavioral modification trial (≥3 months), age and baseline BMI/comorbidity pathways, and requirement to use with behavioral modification and reduced‑calorie diet. Documentation required.

Initial therapy

Initial therapy approvals are time‑limited (example: 7–8 months) and require meeting all initial criteria.

Initial therapy (general)

Age: Patient is ≥ 18 years of age≥18 yrs

Continuation Therapy Criteria

Continuation therapy requirements

Continuation (renewal) approvals require demonstration of specified weight loss (product‑specific) and ongoing use with behavioral modification.

Continuation therapy requirements: Product‑specific continuation criteria

Examples: Saxenda adult continuation requires ≥4% weight loss; Wegovy adult continuation requires ≥5% weight loss; pediatric continuation requires ≥1% BMI reduction (patients ≥12 and <18 years). Documentation of baseline eligibility and weight change required.

Continuation therapy rules

Continuation approvals are available (commonly 1 year) when documented weight loss and other continuation criteria are met.

Continuation (general)

Duration: Patient has completed the applicable initial therapy period or has prior approval for continuation

Step Therapy Requirements

Step	Requirement	Duration / Notes
1
Patient has been enrolled in and engaged with a behavioral/lifestyle program (standard lifestyle vendor) with documented participation (e.g., weigh-ins, app engagements).
Behavioral program engagement is required prior to approval; engagement examples include four weigh-ins/month and four app engagements/month as an additional benefit coverage requirement.

Step	Requirement	Duration / Notes
1
Trial of behavioral modification and dietary restriction for at least 3 months prior to initiating medication; documentation required.
Minimum 3-month trial before initiation; required for initial therapy approvals (example: initial approval for weight-loss indication is 8 months when criteria met).

Site of Care and Program Engagement

Prior Authorization

Enrollment and minimum lifestyle‑program engagement required

Patient must be enrolled and engaged in the payer’s standard lifestyle vendor program and complete four weigh‑ins per month plus four app engagements per month as an additional benefit coverage requirement.

Note

Site‑of‑care and clinical appropriateness requirement

Ensure dosage, frequency, duration, and site of care are reasonable and clinically appropriate, supported by evidence‑based literature, and adjusted based on severity, alternative treatments, and prior response when requesting coverage.

Background

BACKGROUND — Saxenda, Wegovy, and Zepbound are glucagon‑like peptide‑1 (GLP‑1) receptor agonists; Zepbound also has glucose‑dependent insulinotropic polypeptide (GIP) activity. These agents are indicated as adjuncts to a reduced‑calorie diet and increased physical activity for weight management in adults and certain pediatric patients. The prescribing information and this policy advise that none of the GLP‑1 or GLP‑1/GIP agonists be coadministered together, and the policy clarifies that concomitant use with other FDA‑approved weight‑loss medications is not recommended and is considered not medically necessary.

Definitions

inv-21: Obesity classes (CDC)

Obesity Class 1BMI ≥ 30 to < 35 kg/m2

Obesity Class 2BMI ≥ 35 to < 40 kg/m2

Obesity Class 3BMI ≥ 40 kg/m2

inv-22: Apnea-Hypopnea Index (AHI)

DefinitionApnea‑Hypopnea Index (AHI) = number of apneas and hypopneas per hour of sleep

Moderate OSAAHI ≥ 15 events per hour

Severe OSAAHI ≥ 30 events per hour

Policy Summary

PayerCigna

PolicyGlucagon-Like Peptide-1 Agonists BMI ≥ 32

Policy CodePolicy IP0621

Change TypeMaterial revisions to comorbidity definitions, concomitant therapy exclusions, and continuation durations

Effective DateSep 15, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documentation of baseline BMI, trial of behavioral modification (≥3 months), and required comorbidity or weight-loss response criteria.

SourceLink

On This Page

Wegovy Continuing Therapy (Pediatric 12 to <18): Approve for 1 year if ALL are met

Wegovy Initial Therapy (CV risk reduction - Adults): Approve for initial therapy if ALL are met

i. Patient is ≥ 18 years of age; ii. Patient has a current BMI ≥ 27 kg/m2; iii. Patient has either prior myocardial infarction, prior stroke (not TIA), or symptomatic peripheral arterial disease evidenced by ABI <0.85, peripheral revascularization, or amputation for atherosclerotic disease; iv. Prescriber states medication will be used in combination with optimized pharmacotherapy for established CVD; v. Medication will be used concomitantly with behavioral modification and a reduced‑calorie diet. Documentation required.

Wegovy Continuing Therapy (CV risk reduction - Adults): Approve for 1 year if ALL are met

i. Patient is ≥ 18 years of age; ii. At baseline patient had a BMI ≥ 27 kg/m2; iii. Same qualifying CVD history as initial; iv. Medication used in combination with optimized pharmacotherapy for established CVD; v. Medication will be used concomitantly with behavioral modification and a reduced‑calorie diet. Documentation required.

documentation required; comorbidities may be baseline or current

Concomitant use: Medication will be used concomitantly with behavioral modification and a reduced‑calorie diet

prescriber attestation/documentation required

Initial Therapy (alternative sections)

Concomitant use: Medication will be used with behavioral modification and a reduced‑calorie diet

documentation required

Continuation Therapy (prescriber assessment)

Exclusions: Patient does NOT have central sleep apnea with ≥50% central events and does NOT have Cheyne‑Stokes respiration

if present not approved

Concomitant use: Medication will be used concomitantly with behavioral modification and a reduced‑calorie diet

documentation required

Patient is ≥ 12 years of age and < 18 years of age (documentation required)

Behavioral program prerequisiteTrial of behavioral modification and dietary restriction for at least 3 months (documentation required)

inv-11: BMI thresholds

Baseline BMI optionsBaseline BMI ≥ 32 kg/m2 OR baseline BMI ≥ 27 kg/m2 with ≥2 weight-related comorbidities (documentation required)

Current BMI for OSA indicationCurrent BMI ≥ 30 kg/m2 required for obstructive sleep apnea indication (documentation required)

Baseline definitionBaseline refers to BMI measured prior to initiation of any GLP-1 or GLP-1/GIP agonist (documentation required)

Documentation of two weight-related comorbidities when applicable

Weight change documentation (e.g., ≥4% at 16 weeks for Saxenda adults; ≥5% for Zepbound continuation)

Sleep study report with AHI for OSA criteria

Prior Authorization

Behavioral Modification Prerequisite and Ongoing Engagement

Patients must be actively enrolled in and engaged with the standard lifestyle/vendor program while on therapy. The program requires completion of four weigh-ins per month and four app engagements per month; engagements may include lesson completion, recorded meals, weigh-ins, glucose or blood pressure readings, community engagement, or goal setting/achievement.

Member enrollment and ongoing engagement with lifestyle vendor program (4 weigh-ins/month and 4 app engagements/month)

Denial Risk

Concomitant Therapy Exclusions

Do not prescribe or approve concomitant use of Saxenda, Wegovy, or Zepbound with other FDA‑approved weight‑loss medications or with other GLP‑1 or GLP‑1/GIP receptor agonists. Examples include, but are not limited to, phentermine, benzphetamine, diethylpropion, phendimetrazine, Contrave (naltrexone/bupropion), phentermine/topiramate (Qsymia), orlistat (Xenical/Alli), and other GLP‑1 agents such as Ozempic, Rybelsus, Trulicity, Victoza, exenatide, and tirzepatide (Mounjaro).

Concomitant use with other FDA‑approved weight‑loss medications is not recommended
Do not combine GLP‑1 or GLP‑1/GIP agonists with each other

Note

Dosing and Coadministration

Dose escalation and maintenance dosing follow manufacturers' prescribing information: Wegovy escalation to 2.4 mg by week 17 (maintenance 2.4 mg or 1.7 mg weekly); Saxenda escalation over 4 weeks with maintenance 3 mg daily (evaluate weight loss at 16 weeks and discontinue if <4% in adults); Zepbound starting 2.5 mg weekly with escalation to maintenance doses of 5, 10, or 15 mg weekly (maximum 15 mg). Do NOT coadminister GLP‑1/GLP‑1–GIP agonists with each other.

Follow product-specific escalation schedules and maintenance doses
If intolerance occurs, consider delaying escalation or reducing to prior tolerated dose
Evaluate response thresholds per product labeling (e.g., Saxenda 16-week rule)

Behavioral modification: Trial of behavioral modification and dietary restriction for at least 3 months

documentation required

BMI/comorbidity: Baseline BMI ≥32 kg/m2 OR baseline BMI ≥27 kg/m2 with ≥2 specified weight‑related comorbidities

documentation required; comorbidities list per policy

Concomitant use: Medication will be used with behavioral modification and a reduced‑calorie diet

documentation required

Initial therapy (duration note)

approval durations updated to 1 year in revisions

Weight loss threshold: Patient has lost ≥5% of baseline body weight (or ≥4% for Saxenda adult; ≥10% for certain OSA continuation criteria)≥4%/≥5%/≥10%

documentation required

Prescriber assessment: Prescriber documents ongoing clinical benefit and continued engagement in behavioral modification/reduced‑calorie diet

documentation required

Continuation (exceptions/notes)

inv-23: Baseline BMI

Definition of baseline BMIBMI measured prior to initiation of any GLP‑1 or GLP‑1/GIP agonist therapy (documentation required)

Use in continuation decisionsBaseline BMI is the reference for assessing eligibility and percent weight‑loss thresholds for continuation (e.g., ≥4% or ≥5% depending on agent)

Documentation requirementBaseline BMI must be documented in the medical record or supporting documentation submitted for prior authorization